A new report predicts that the RSV (Respiratory Syncytial Virus) vaccine market will exceed $9 billion by 2029. As the RSV season is about to begin in September, pharmaceutical companies like Moderna and AstraZeneca are expected to enter the market with their respective vaccines – mRNA-1345 and Beyfortus. The report highlights the increasing demand for RSV vaccines due to the rising cases of respiratory infections, particularly in infants and older adults. The market is also driven by government initiatives to reduce the burden of RSV-related hospitalizations. With the potential for significant growth in the coming years, the RSV vaccine market is poised to offer lucrative opportunities for players in the pharmaceutical industry.
Today: December 6, 2023